Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1231.85
-13.65 (-1.10%)
< Home < Back

Dr. Reddy's launches Naloxone Hydrochloride Injection

Date: 19-03-2020

Dr. Reddy’s Laboratories has launched Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA).

The Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) had U.S. sales of approximately $31 million MAT for the most recent twelve months ending in January 2020. The company’s Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) is available in 2 ml single-dose prefilled syringe.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.